SpineGuard Completes €1.2M Capital Increase to Expand DSG Technology

SpineGuard, a French medical device company focusing on digital surgical guidance (DSG®) technology, has successfully completed a capital increase totaling €1.2 million. This financing effort, conducted without shareholders' preferential rights but with a priority period, reflects the company's commitment to advancing its international commercial efforts and technological expansions.

The funds raised are intended to bolster SpineGuard's financial structure and support the development and promotion of its DSG technology for new applications such as orthopedic drills, dental implantology, and surgical robotics. This comes amidst the company's strategic measures to collaborate with global partners, including Omnia Medical in the United States, aiming for operational break-even by late 2026.

Settlement and trading of the newly issued shares on the Euronext Growth Paris market are set for December 18, 2025. The capital increase results in the creation of over 10 million new shares, raising the company's total share capital and slightly altering its shareholder structure.